Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Malignancy in Giant Cell Tumor of Bone: A Review of the Literature.

Palmerini E, Picci P, Reichardt P, Downey G.

Technol Cancer Res Treat. 2019 Jan 1;18:1533033819840000. doi: 10.1177/1533033819840000.

2.

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N.

Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25.

3.

Filamin A Phosphorylation at Serine 2152 by the Serine/Threonine Kinase Ndr2 Controls TCR-Induced LFA-1 Activation in T Cells.

Waldt N, Seifert A, Demiray YE, Devroe E, Turk BE, Reichardt P, Mix C, Reinhold A, Freund C, Müller AJ, Schraven B, Stork O, Kliche S.

Front Immunol. 2018 Dec 4;9:2852. doi: 10.3389/fimmu.2018.02852. eCollection 2018.

4.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

5.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv268-iv269. doi: 10.1093/annonc/mdy321. No abstract available.

6.

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.

Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA.

World J Surg Oncol. 2018 Sep 19;16(1):191. doi: 10.1186/s12957-018-1478-3.

7.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv267. doi: 10.1093/annonc/mdy320. No abstract available.

8.

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-E.W.I.N.G.99 and EWING-2008 Investigators.

J Clin Oncol. 2018 Sep 6:JCO2018782516. doi: 10.1200/JCO.2018.78.2516. [Epub ahead of print]

9.

The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.

Reichardt P.

Oncol Res Treat. 2018;41(7-8):472-477. doi: 10.1159/000487511. Epub 2018 Jun 13.

PMID:
29895025
10.

High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients.

Schuster AJ, Kager L, Reichardt P, Baumhoer D, Csóka M, Hecker-Nolting S, Lang S, Lorenzen S, Mayer-Steinacker R, von Kalle T, Kevric M, Werner M, Windhager R, Wirth T, Bielack SS.

Sarcoma. 2018 May 2;2018:1632978. doi: 10.1155/2018/1632978. eCollection 2018.

11.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv68-iv78. doi: 10.1093/annonc/mdy095. No abstract available.

PMID:
29846513
12.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv51-iv67. doi: 10.1093/annonc/mdy096. No abstract available.

PMID:
29846498
13.

Options for treating different soft tissue sarcoma subtypes.

Ray-Coquard I, Serre D, Reichardt P, Martín-Broto J, Bauer S.

Future Oncol. 2018 May;14(10s):25-49. doi: 10.2217/fon-2018-0076. Review.

PMID:
29768052
14.

Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.

Reichardt P, Tabone MD, Mora J, Morland B, Jones RL.

Future Oncol. 2018 Oct;14(25):2663-2676. doi: 10.2217/fon-2018-0210. Epub 2018 May 11. Review.

15.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2019 Feb 1;30(2):344. doi: 10.1093/annonc/mdx823. No abstract available.

16.

Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.

Muehlberg F, Funk S, Zange L, von Knobelsdorff-Brenkenhoff F, Blaszczyk E, Schulz A, Ghani S, Reichardt A, Reichardt P, Schulz-Menger J.

ESC Heart Fail. 2018 Aug;5(4):620-629. doi: 10.1002/ehf2.12277. Epub 2018 Apr 19.

17.

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.

Liu J, Nicum S, Reichardt P, Croitoru K, Illek B, Schmidinger M, Rogers C, Whalen C, Jayson GC.

Gynecol Oncol. 2018 Jul;150(1):173-179. doi: 10.1016/j.ygyno.2018.03.058. Epub 2018 Apr 5. Review.

PMID:
29627080
18.

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.

Ihle MA, Huss S, Jeske W, Hartmann W, Merkelbach-Bruse S, Schildhaus HU, Büttner R, Sihto H, Sundby Hall K, Eriksson M, Reichardt P, Joensuu H, Wardelmann E.

PLoS One. 2018 Feb 16;13(2):e0193048. doi: 10.1371/journal.pone.0193048. eCollection 2018.

19.

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.

Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, Ghadjar P, Hohenberger P, Angele M, Salat C, Vujaskovic Z, Daugaard S, Mella O, Mansmann U, Dürr HR, Knösel T, Abdel-Rahman S, Schmidt M, Hiddemann W, Jauch KW, Belka C, Gronchi A; European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology.

JAMA Oncol. 2018 Apr 1;4(4):483-492. doi: 10.1001/jamaoncol.2017.4996.

20.

CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.

Schmalenberg H, Al-Batran SE, Pauligk C, Zander T, Reichart A, Lindig U, Kleiß M, Müller L, Bolling C, Seufferlein T, Reichardt P, Kullmann F, Eschenburg H, Schmittel A, Egger M, Block A, Goetze TO.

J Cancer Res Clin Oncol. 2018 Mar;144(3):559-569. doi: 10.1007/s00432-017-2565-5. Epub 2017 Dec 28.

PMID:
29285668
21.

EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.

Ferrari S, Bielack SS, Smeland S, Longhi A, Egerer G, Sundby Hall K, Donati D, Kevric M, Brosjö O, Comandone A, Werner M, Monge O, Palmerini E, Berdel WE, Bjerkehagen B, Paioli A, Lorenzen S, Eriksson M, Gambarotti M, Tunn PU, Jebsen NL, Cesari M, von Kalle T, Ferraresi V, Schwarz R, Bertulli R, Kasparek AK, Grignani G, Krasniqi F, Sorg B, Hecker-Nolting S, Picci P, Reichardt P.

Tumori. 2018 Jan-Feb;104(1):30-36. doi: 10.5301/tj.5000696.

PMID:
29218692
22.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
23.

Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management.

Gaebler M, Silvestri A, Haybaeck J, Reichardt P, Lowery CD, Stancato LF, Zybarth G, Regenbrecht CRA.

Front Oncol. 2017 Sep 11;7:203. doi: 10.3389/fonc.2017.00203. eCollection 2017. Review.

24.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2017 Dec 1;28(12):3000-3008. doi: 10.1093/annonc/mdx527. Erratum in: Ann Oncol. 2019 Feb 1;30(2):344.

25.

TCR signalling network organization at the immunological synapses of murine regulatory T cells.

van Ham M, Teich R, Philipsen L, Niemz J, Amsberg N, Wissing J, Nimtz M, Gröbe L, Kliche S, Thiel N, Klawonn F, Hubo M, Jonuleit H, Reichardt P, Müller AJ, Huehn J, Jänsch L.

Eur J Immunol. 2017 Dec;47(12):2043-2058. doi: 10.1002/eji.201747041. Epub 2017 Sep 12.

26.

Genotoxicity testing of different surface-functionalized SiO2, ZrO2 and silver nanomaterials in 3D human bronchial models.

Haase A, Dommershausen N, Schulz M, Landsiedel R, Reichardt P, Krause BC, Tentschert J, Luch A.

Arch Toxicol. 2017 Dec;91(12):3991-4007. doi: 10.1007/s00204-017-2015-9. Epub 2017 Jun 22.

PMID:
28643002
27.

Review of past and present clinical cases with a view to future treatment options.

Martín-Broto J, Reichardt P, Stacchiotti S, Blay JY.

Future Oncol. 2017 Jun;13(13s):11-28. doi: 10.2217/fon-2017-0120. Epub 2017 May 2. Review.

PMID:
28460536
28.

Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial.

Frank JA, Ranft A, Paulussen M, Juergens H, Kruseova J, Bauer S, Niggli F, Reichardt P, Dirksen U.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26524. Epub 2017 Apr 24.

PMID:
28436593
29.

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.

Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P.

Ann Oncol. 2017 Mar 1;28(3):541-546. doi: 10.1093/annonc/mdw659.

30.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group.

J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.

PMID:
28362562
31.

SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour.

Pulkka OP, Nilsson B, Sarlomo-Rikala M, Reichardt P, Eriksson M, Hall KS, Wardelmann E, Vehtari A, Joensuu H, Sihto H.

Br J Cancer. 2017 Apr 25;116(9):1195-1202. doi: 10.1038/bjc.2017.82. Epub 2017 Mar 23.

32.

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.

JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751.

33.

Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).

Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P.

Eur J Cancer. 2017 May;76:60-67. doi: 10.1016/j.ejca.2017.02.001. Epub 2017 Mar 8.

PMID:
28282612
34.

The importance of treating by histological subtype in advanced soft tissue sarcoma.

Martín Broto J, Le Cesne A, Reichardt P.

Future Oncol. 2017 Jan;13(1s):23-31. Review.

PMID:
27918201
35.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS.

Lancet Oncol. 2016 Oct;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25.

36.

Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.

Schuler MK, Gerdes S, West A, Richter S, Busemann C, Hentschel L, Lenz F, Kopp HG, Ehninger G, Reichardt P, Pink D.

BMC Cancer. 2016 Aug 9;16:619. doi: 10.1186/s12885-016-2654-x.

37.

Quantification and visualization of cellular uptake of TiO2 and Ag nanoparticles: comparison of different ICP-MS techniques.

Hsiao IL, Bierkandt FS, Reichardt P, Luch A, Huang YJ, Jakubowski N, Tentschert J, Haase A.

J Nanobiotechnology. 2016 Jun 22;14(1):50. doi: 10.1186/s12951-016-0203-z.

38.

Time-of-flight secondary ion mass spectrometry (ToF-SIMS)-based analysis and imaging of polyethylene microplastics formation during sea surf simulation.

Jungnickel H, Pund R, Tentschert J, Reichardt P, Laux P, Harbach H, Luch A.

Sci Total Environ. 2016 Sep 1;563-564:261-6. doi: 10.1016/j.scitotenv.2016.04.025. Epub 2016 Apr 30.

PMID:
27135589
39.

Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?

Eriksson M, Reichardt P, Sundby Hall K, Schütte J, Cameron S, Hohenberger P, Bauer S, Leinonen M, Reichardt A, Rejmyr Davis M, Alvegård T, Joensuu H.

Eur J Cancer. 2016 May;59:128-133. doi: 10.1016/j.ejca.2016.02.021. Epub 2016 Mar 28.

PMID:
27033260
40.

[Soft tissue sarcomas and gastrointestinal stromal tumors].

Reichardt P.

Internist (Berl). 2016 Mar;57(3):245-56. doi: 10.1007/s00108-016-0021-2. German.

PMID:
26907871
41.
42.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC.

BMC Cancer. 2016 Jan 15;16:22. doi: 10.1186/s12885-016-2051-5.

43.

Erratum: Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW.

Geburtshilfe Frauenheilkd. 2015 Oct;75(10):e3.

44.

Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.

Andreou D, Werner M, Pink D, Traub F, Schuler MK, Gosheger G, Jobke B, Reichardt P, Tunn PU.

Int J Hyperthermia. 2016;32(2):159-64. doi: 10.3109/02656736.2015.1109146. Epub 2015 Dec 15.

PMID:
26670477
45.

Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW.

Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1028-1042. Erratum in: Geburtshilfe Frauenheilkd. 2015 Oct;75(10):e3.

46.

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P.

J Clin Oncol. 2016 Jan 20;34(3):244-50. doi: 10.1200/JCO.2015.62.9170. Epub 2015 Nov 2.

PMID:
26527782
47.

The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.

Barrios CH, Blackstein ME, Blay JY, Casali PG, Chacon M, Gu J, Kang YK, Nishida T, Purkayastha D, Woodman RC, Reichardt P.

Eur J Cancer. 2015 Nov;51(16):2423-33. doi: 10.1016/j.ejca.2015.07.010. Epub 2015 Aug 3.

48.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC.

Oncologist. 2015 Jul;20(7):823-30. doi: 10.1634/theoncologist.2014-0471. Epub 2015 Jun 12. Review.

49.

Trabectedin clinical cases: use according to indication in diverse clinical scenarios.

Grignani G, Martín-Broto J, Schuler M, Reichardt P.

Future Oncol. 2015;11(11 Suppl):15-24. doi: 10.2217/fon.15.76.

PMID:
26043311
50.

Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.

Le Cesne A, Reichardt P.

Future Oncol. 2015;11(11 Suppl):3-14. doi: 10.2217/fon.15.78. Review.

PMID:
26043310

Supplemental Content

Loading ...
Support Center